hiv infections

Summary

Summary: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Top Publications

  1. pmc Prevention of HIV-1 infection with early antiretroviral therapy
    Myron S Cohen
    University of North Carolina at Chapel Hill, Institute for Global Health and Infectious Diseases, Suite 2115, Bioinformatics Bldg, 130 Mason Farm Rd, CB 7030, Chapel Hill, NC 27599, USA
    N Engl J Med 365:493-505. 2011
  2. pmc Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    Quarraisha Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Durban 4013, South Africa
    Science 329:1168-74. 2010
  3. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  4. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
  5. doi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
  6. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
  7. pmc SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
    Nadine Laguette
    Institut de Genetique Humaine, Laboratoire de Virologie Moleculaire, CNRS UPR1142, Montpellier 34000, France
    Nature 474:654-7. 2011
  8. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
  9. pmc Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
  10. pmc Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
    Kasia Hrecka
    Department of Molecular Biology and Microbiology, Case School of Medicine, Cleveland, Ohio 44106, USA
    Nature 474:658-61. 2011

Research Grants

  1. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2002
  2. Health of HIV-Infected Mothers after pMTCT, Botswana
    Shahin Lockman; Fiscal Year: 2007
  3. HIV/STD Risk Reduction For African American Couples
    Nabila El Bassel; Fiscal Year: 2002
  4. HIV/AIDS Risk Reduction for African American Couples
    Nabila El Bassel; Fiscal Year: 2008
  5. HIV/AIDS Risk Reduction for African American Couples
    Nabila El Bassel; Fiscal Year: 2007
  6. HIV/STI Risks Among Migrant Market Workers in Kazakhstan
    Nabila El Bassel; Fiscal Year: 2009
  7. Multimedia HIV/STI Prevention for Drug-Involved Female Offenders
    Nabila El Bassel; Fiscal Year: 2008
  8. PARTNER ABUSE AND HIV IN WOMEN RECEIVING EMERGENCY CARE
    Nabila El Bassel; Fiscal Year: 2001
  9. HIV/STI Prevention for Drug-Involved Couples
    Nabila El Bassel; Fiscal Year: 2007
  10. HIV/STI Prevention for Drug-Involved Couples
    Nabila El Bassel; Fiscal Year: 2006

Detail Information

Publications277 found, 100 shown here

  1. pmc Prevention of HIV-1 infection with early antiretroviral therapy
    Myron S Cohen
    University of North Carolina at Chapel Hill, Institute for Global Health and Infectious Diseases, Suite 2115, Bioinformatics Bldg, 130 Mason Farm Rd, CB 7030, Chapel Hill, NC 27599, USA
    N Engl J Med 365:493-505. 2011
    ..Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples...
  2. pmc Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    Quarraisha Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Durban 4013, South Africa
    Science 329:1168-74. 2010
    ..Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use...
  3. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  4. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
    ..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk...
  5. doi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
    ..This effort illustrates the power with which RNA interference and forward genetics can be used to expose the dependencies of human pathogens such as HIV, and in so doing identify potential targets for therapy...
  6. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
    ....
  7. pmc SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
    Nadine Laguette
    Institut de Genetique Humaine, Laboratoire de Virologie Moleculaire, CNRS UPR1142, Montpellier 34000, France
    Nature 474:654-7. 2011
    ..Our results demonstrate that SAMHD1 is an antiretroviral protein expressed in cells of the myeloid lineage that inhibits an early step of the viral life cycle...
  8. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
    ..Vpu co-localized with CD317 and inhibited these effects. Inhibition of Vpu function and consequent mobilization of tetherin's antiviral activity is a potential therapeutic strategy in HIV/AIDS...
  9. pmc Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
    ..Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition...
  10. pmc Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
    Kasia Hrecka
    Department of Molecular Biology and Microbiology, Case School of Medicine, Cleveland, Ohio 44106, USA
    Nature 474:658-61. 2011
    ....
  11. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
    ..Comparison of the crystal structure of one of the antibodies to the broadly neutralizing antibody VRC01 revealed conservation of the contacts to the HIV spike...
  12. pmc The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
    Florencia Pereyra
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology MIT and Harvard, Boston, MA, USA
    Science 330:1551-7. 2010
    ..These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection...
  13. doi Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
    Reuben M Granich
    Department of HIV AIDS, WHO, Geneva, Switzerland
    Lancet 373:48-57. 2009
    ..We investigated a theoretical strategy of universal voluntary HIV testing and immediate treatment with ART, and examined the conditions under which the HIV epidemic could be driven towards elimination...
  14. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
    ..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
  15. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  16. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  17. ncbi 2011 update of the drug resistance mutations in HIV-1
    Victoria A Johnson
    Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    Top Antivir Med 19:156-64. 2011
    ..This November 2011 edition of the IAS-USA drug resistance mutations list updates the figures last published in December 2010 (Johnson VA et al, Top HIV Med, 2010;18:156-163)...
  18. ncbi Adherence to medication
    Lars Osterberg
    General Medicine Division, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    N Engl J Med 353:487-97. 2005
  19. doi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
    ..This study highlights both the power and shortcomings of large scale loss-of-function screens in discovering host-pathogen interactions...
  20. pmc Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
    ..Taken together, the multiscale approach described here has uncovered multiprotein virus-host interactions that likely act in concert to facilitate the early steps of HIV-1 infection...
  21. pmc Estimated HIV incidence in the United States, 2006-2009
    Joseph Prejean
    Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS ONE 6:e17502. 2011
    The estimated number of new HIV infections in the United States reflects the leading edge of the epidemic. Previously, CDC estimated HIV incidence in the United States in 2006 as 56,300 (95% CI: 48,200-64,500)...
  22. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
    ..Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners...
  23. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  24. pmc Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review
    Sydney Rosen
    Center for Global Health and Development, Boston University, Boston, Massachusetts, USA
    PLoS Med 8:e1001056. 2011
    ..We conducted a systematic review of pre-ART retention in care in Africa...
  25. pmc Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    Xueling Wu
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Science 333:1593-602. 2011
    ....
  26. pmc The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
    ....
  27. pmc HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study
    R K Heaton
    University of California, San Diego, USA
    Neurology 75:2087-96. 2010
    ....
  28. pmc HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4781-9. 2006
    ..Thus, rather than quantity or phenotype, the quality of the CD8(+) T-cell functional response serves as an immune correlate of HIV disease progression and a potential qualifying factor for evaluation of HIV vaccine efficacy...
  29. doi Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia, USA
    JAMA 304:321-33. 2010
    ....
  30. ncbi Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis
    Suzanna Attia
    Institute of Social and Preventive Medicine, University of Bern, Switzerland
    AIDS 23:1397-404. 2009
    ..To synthesize the evidence on the risk of HIV transmission through unprotected sexual intercourse according to viral load and treatment with combination antiretroviral therapy (ART)...
  31. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
    ..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
  32. doi Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial
    Richard T Lester
    Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya
    Lancet 376:1838-45. 2010
    ..We aimed to assess whether mobile phone communication between health-care workers and patients starting antiretroviral therapy in Kenya improved drug adherence and suppression of plasma HIV-1 RNA load...
  33. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
    ..Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations...
  34. pmc Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders
    Cristian Pop-Eleches
    School of International and Public Affairs, Columbia University, New York, New York, USA
    AIDS 25:825-34. 2011
    ..This study tested the efficacy of short message service (SMS) reminders on adherence to ART among patients attending a rural clinic in Kenya...
  35. pmc Global trends in molecular epidemiology of HIV-1 during 2000-2007
    Joris Hemelaar
    Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, UK
    AIDS 25:679-89. 2011
    ..To estimate the global and regional distribution of HIV-1 subtypes and recombinants between 2000 and 2007...
  36. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  37. pmc Effect of early versus deferred antiretroviral therapy for HIV on survival
    Mari M Kitahata
    University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359931, Seattle, WA 98104, USA
    N Engl J Med 360:1815-26. 2009
    ..The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain...
  38. ncbi The challenge of finding a cure for HIV infection
    Douglas D Richman
    San Diego VA Healthcare System and University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0679, USA
    Science 323:1304-7. 2009
    ..This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure...
  39. ncbi Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial
    Ronald H Gray
    Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21215, USA
    Lancet 369:657-66. 2007
    ..Ecological and observational studies suggest that male circumcision reduces the risk of HIV acquisition in men. Our aim was to investigate the effect of male circumcision on HIV incidence in men...
  40. pmc Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Lancet 376:532-9. 2010
    ..We aimed to estimate the association between plasma HIV-1 viral load, HAART coverage, and number of new cases of HIV in the population of a Canadian province...
  41. doi Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study
    Ilesh V Jani
    Instituto Nacional da Saúde, Maputo, Mozambique
    Lancet 378:1572-9. 2011
    ..We implemented point-of-care counting of CD4 cells in Mozambique and assessed the effect on loss to follow-up before immunological staging and treatment initiation...
  42. ncbi Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs
    Gary Marks
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention CDC, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 39:446-53. 2005
    ..To compare the prevalence of high-risk sexual behaviors in HIV persons aware of their serostatus with that in HIV persons unaware of their status in the United States and to discuss implications for HIV prevention programs...
  43. ncbi Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial
    Robert C Bailey
    Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL 60612, USA
    Lancet 369:643-56. 2007
    ..Our aim was to determine whether male circumcision had a protective effect against HIV infection, and to assess safety and changes in sexual behaviour related to this intervention...
  44. pmc Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
    Elena E Perez
    Abramson Family Cancer Research Institute, Department of Pathology and Laboratory Medicine, 421 Curie Blvd, Room 554, BRB II III, Philadelphia, Pennsylvania 19104 6160, USA
    Nat Biotechnol 26:808-16. 2008
    ..Thus adoptive transfer of ex vivo expanded CCR5 ZFN-modified autologous CD4(+) T cells in HIV patients is an attractive approach for the treatment of HIV-1 infection...
  45. pmc Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation
    Liang Shan
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Immunity 36:491-501. 2012
    ..These results demonstrate that stimulating HIV-1-specific CTLs prior to reactivating latent HIV-1 may be essential for successful eradication efforts and should be considered in future clinical trials...
  46. ncbi CD4+ count-guided interruption of antiretroviral treatment
    W M El-Sadr
    Division of Infectious Diseases, Harlem Hospital Center and Columbia University, New York, NY 10037, USA
    N Engl J Med 355:2283-96. 2006
    ..Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV)...
  47. pmc Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review
    Matthew P Fox
    Center for Global Health and Development, Boston University, Boston, MA 02118, USA
    Trop Med Int Health 15:1-15. 2010
    ..To estimate the proportion of all-cause adult patient attrition from antiretroviral therapy (ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment...
  48. doi Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy
    Alex Sigal
    Division of Biology, California Institute of Technology, Pasadena, California 91125, USA
    Nature 477:95-8. 2011
    ....
  49. ncbi Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA
    Gary Marks
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention CDC, Atlanta, Georgia 30333, USA
    AIDS 20:1447-50. 2006
    New HIV infections stem from people who are aware they are HIV positive (approximately 75% of infected persons in the USA) and those who are unaware of their HIV-positive status (approximately 25%).
  50. pmc Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 197:126-33. 2008
    ....
  51. doi Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, 131 Ponce de Leon Ave NE, Ste 130, Atlanta, GA 30308, USA
    JAMA 308:387-402. 2012
    ..New trial data and drug regimens that have become available in the last 2 years warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected adults in resource-rich settings...
  52. ncbi Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
    Matthias Egger
    Department of Social and Preventive Medicine, University of Bern, CH 3012 Bern, Switzerland
    Lancet 360:119-29. 2002
    ..The ART Cohort Collaboration, which includes 13 cohort studies from Europe and North America, was established to fill this knowledge gap...
  53. pmc Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis
    Martin W G Brinkhof
    Division of International and Environmental Health, Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    PLoS ONE 4:e5790. 2009
    ..The retention of patients in antiretroviral therapy (ART) programmes is an important issue in resource-limited settings. Loss to follow up can be substantial, but it is unclear what the outcomes are in patients who are lost to programmes...
  54. pmc A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells
    Nicolas Manel
    Molecular Pathogenesis Program, The Kimmel Center for Biology and Medicine of the Skirball Institute, New York University School of Medicine, New York, New York 10016, USA
    Nature 467:214-7. 2010
    ..The virulence of HIV-1 may be related to evasion of this response, the manipulation of which may be necessary to generate an effective HIV-1 vaccine...
  55. pmc The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection
    Edward M Gardner
    Denver Public Health, Denver, Colorado, USA
    Clin Infect Dis 52:793-800. 2011
    ....
  56. pmc Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
    R Brad Jones
    Department of Immunology, University of Toronto, Toronto, ON, Canada
    J Exp Med 205:2763-79. 2008
    ..Blocking the Tim-3 signaling pathway restored proliferation and enhanced cytokine production in HIV-1-specific T cells. Thus, Tim-3 represents a novel target for the therapeutic reversal of HIV-1-associated T cell dysfunction...
  57. doi Tuberculosis
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
    Lancet 378:57-72. 2011
    ....
  58. doi Towards an improved investment approach for an effective response to HIV/AIDS
    Bernhard Schwartlander
    Joint United Nations Programme on HIV AIDS, Geneva, Switzerland
    Lancet 377:2031-41. 2011
    ..Implementation of the new investment framework would avert 12·2 million new HIV infections and 7·4 million deaths from AIDS between 2011 and 2020 compared with continuation of present approaches, and ..
  59. doi The costs and effectiveness of four HIV counseling and testing strategies in Uganda
    Nick Menzies
    US Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Atlanta, Georgia, USA
    AIDS 23:395-401. 2009
    ..HIV counseling and testing (HCT) is a key intervention for HIV/AIDS control, and new strategies have been developed for expanding coverage in developing countries. We compared costs and outcomes of four HCT strategies in Uganda...
  60. pmc Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
    ..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
  61. pmc Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    Davide Corti
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    PLoS ONE 5:e8805. 2010
    ....
  62. doi Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana
    Michael C Thigpen
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, USA
    N Engl J Med 367:423-34. 2012
    ..Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain...
  63. pmc Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010
    ..Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1...
  64. pmc CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Dr, Room 3509, Bethesda, MD 20892, USA
    J Exp Med 200:749-59. 2004
    ....
  65. pmc Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism
    Janet L Douglas
    Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
    J Virol 83:7931-47. 2009
    ..Understanding the molecular mechanisms of both Vpu-dependent and -independent mediated antagonism of BST-2 will be critical for therapeutic strategies that exploit this novel viral function...
  66. ncbi HIV infection and multidrug-resistant tuberculosis: the perfect storm
    Charles D Wells
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S86-107. 2007
    ..The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB prevalence...
  67. pmc Timing of initiation of antiretroviral drugs during tuberculosis therapy
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    N Engl J Med 362:697-706. 2010
    ..The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial...
  68. pmc Common genetic variation and the control of HIV-1 in humans
    Jacques Fellay
    Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    PLoS Genet 5:e1000791. 2009
    ..This study thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians...
  69. pmc High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men
    Hui Li
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS Pathog 6:e1000890. 2010
    ....
  70. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..The characterization of primary HIV infection by the analysis of serial plasma samples from newly infected persons using multiple standard viral assays...
  71. pmc Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
    ..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  72. pmc The immune response during acute HIV-1 infection: clues for vaccine development
    Andrew J McMichael
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Nat Rev Immunol 10:11-23. 2010
    ..In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine...
  73. pmc Projections of global mortality and burden of disease from 2002 to 2030
    Colin D Mathers
    Evidence and Information for Policy Cluster, World Health Organization, Geneva, Switzerland
    PLoS Med 3:e442. 2006
    ..This paper describes the methods, assumptions, input data, and results...
  74. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  75. pmc Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes
    Margaret May
    Department of Social Medicine, University of Bristol, Bristol, UK
    Lancet 376:449-57. 2010
    ..We developed two prognostic models to estimate the probability of death in patients starting ART in sub-Saharan Africa...
  76. ncbi Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa
    Kristin L Dunkle
    Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA
    Lancet 363:1415-21. 2004
    ..No study on women has yet assessed gender-based violence as a risk factor for HIV after adjustment for women's own high-risk behaviours, although these are known to be associated with experience of violence...
  77. pmc The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
    Nilu Goonetilleke
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, England, UK
    J Exp Med 206:1253-72. 2009
    ..These included clusters of mutations in envelope that were targeted by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander mutations in linkage with T cell-driven escape...
  78. pmc Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
    Anna Le Tortorec
    Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
    J Virol 83:11966-78. 2009
    ..Finally, we recapitulated these observations in HIV-2-infected CD4+ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication...
  79. pmc Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  80. pmc Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1
    Richard E Haaland
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America
    PLoS Pathog 5:e1000274. 2009
    ....
  81. ncbi Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings
    Bernard M Branson
    Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention proposed, Atlanta, GA 30333, USA
    MMWR Recomm Rep 55:1-17; quiz CE1-4. 2006
    ..Repeat screening in the third trimester is recommended in certain jurisdictions with elevated rates of HIV infection among pregnant women...
  82. pmc HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
    ..We assessed vaccine-induced immunity and its potential contributions to infection risk...
  83. ncbi Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care
    Marielle Bemelmans
    Medecins Sans Frontieres, Blantyre, Malawi
    Trop Med Int Health 15:1413-20. 2010
    ..To describe how district-wide access to HIV/AIDS care was achieved and maintained in Thyolo District, Malawi...
  84. pmc Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
    ..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
  85. ncbi Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    JAMA 296:679-90. 2006
    ..Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa...
  86. ncbi HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells
    James Arthos
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 9:301-9. 2008
    ..On CD4+ T cells, engagement of alpha4beta7 by gp120 resulted in rapid activation of LFA-1, the central integrin involved in the establishment of virological synapses, which facilitate efficient cell-to-cell spreading of HIV-1...
  87. pmc Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
    P Mugyenyi
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 375:123-31. 2010
    ..This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term effect on clinical outcomes in Africa...
  88. pmc Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
    Nathalia Holt
    Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Nat Biotechnol 28:839-47. 2010
    ..The demonstration that a minority of CCR5(-/-) HSPCs can populate an infected animal with HIV-1-resistant, CCR5(-/-) progeny supports the use of ZFN-modified autologous hematopoietic stem cells as a clinical approach to treating HIV-1...
  89. ncbi Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review
    Roos E Barth
    University Medical Centre Utrecht, Department of Internal Medicine and Infectious Diseases, Netherlands
    Lancet Infect Dis 10:155-66. 2010
    ....
  90. pmc Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response
    Beatrice Jacquelin
    Institut Pasteur, Unité de Régulation des Infections Rétrovirales, Paris, France
    J Clin Invest 119:3544-55. 2009
    ..In conclusion, SIV infection triggered a rapid and strong IFN-alpha response in vivo in both AGMs and RMs, with this response being efficiently controlled only in AGMs, possibly as a result of active regulatory mechanisms...
  91. pmc Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry
    Melissa Alexander
    Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Rd, Atlanta, GA 30329, USA
    J Virol 84:4100-4. 2010
    ..Thus, HIV-1 transmission does not appear to select for viruses that can preferentially utilize low levels of entry receptors...
  92. ncbi Child mortality according to maternal and infant HIV status in Zimbabwe
    Edmore Marinda
    ZVITAMBO Project, Harare, Zimbabwe
    Pediatr Infect Dis J 26:519-26. 2007
    ..HIV causes substantial mortality among African children but there is limited data on how this is influenced by maternal or infant infection status and timing...
  93. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
    ..Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere...
  94. pmc HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
    Nicolas Chomont
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal Saint Luc, Montreal, Quebec, Canada
    Nat Med 15:893-900. 2009
    ....
  95. pmc Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
    ..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1...
  96. doi Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes
    Birgitte B Simen
    454 Life Sciences, a Roche Company, Branford, Connecticut, USA
    J Infect Dis 199:693-701. 2009
    ..Minor (i.e., <20% prevalence) drug-resistant human immunodeficiency virus (HIV) variants may go undetected, yet be clinically important...
  97. pmc Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
    Shabbar Jaffar
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 374:2080-9. 2009
    ..Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care...
  98. ncbi Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis
    Marie Louise Newell
    Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London WC1N 1EH, UK
    Lancet 364:1236-43. 2004
    ..With individual data from seven randomised mother-to-child transmission (MTCT) intervention trials, we estimate mortality in African children born to HIV-infected mothers and analyse selected risk factors...
  99. pmc Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e5683. 2009
    ..Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists...
  100. ncbi A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection
    Frederick M Hecht
    University of California San Francisco, San Francisco, CA 94110, USA
    J Infect Dis 194:725-33. 2006
    ....

Research Grants194 found, 100 shown here

  1. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2002
    ..Results of the proposed study will guide the allocation of HIV prevention resources in establishing brief and effective HIV risk reduction counseling services for populations vulnerable to HIV infection. ..
  2. Health of HIV-Infected Mothers after pMTCT, Botswana
    Shahin Lockman; Fiscal Year: 2007
    ..This already-existing cohort with access to ART provides a unique opportunity to answer questions that have significant public health implications with a relatively small investment of additional resources. ..
  3. HIV/STD Risk Reduction For African American Couples
    Nabila El Bassel; Fiscal Year: 2002
    ..The findings will contribute significantly to the field of HIV/STI risk reduction by developing and testing an intervention with African American couples that can be offered to HIV clinics and CBOs. ..
  4. HIV/AIDS Risk Reduction for African American Couples
    Nabila El Bassel; Fiscal Year: 2008
    ..The findings will contribute significantly to an understanding of HIV/STD risk reduction among African American serodiscordant couples, a population at high risk of transmission. ..
  5. HIV/AIDS Risk Reduction for African American Couples
    Nabila El Bassel; Fiscal Year: 2007
    ..The findings will contribute significantly to an understanding of HIV/STD risk reduction among African American serodiscordant couples, a population at high risk of transmission. ..
  6. HIV/STI Risks Among Migrant Market Workers in Kazakhstan
    Nabila El Bassel; Fiscal Year: 2009
    ..The findings from this study will inform future prevention efforts to stem heterosexual transmission of HIV and STIs in Central Asia among male migrant workers. ..
  7. Multimedia HIV/STI Prevention for Drug-Involved Female Offenders
    Nabila El Bassel; Fiscal Year: 2008
    ....
  8. PARTNER ABUSE AND HIV IN WOMEN RECEIVING EMERGENCY CARE
    Nabila El Bassel; Fiscal Year: 2001
    ....
  9. HIV/STI Prevention for Drug-Involved Couples
    Nabila El Bassel; Fiscal Year: 2007
    ..Dr. E1-Bassel, the Social Intervention Group Behavioral Studies at the NY State Psychiatric the study: Dr. Steinglass from the Ackerman Angeles, Dr. Sharp from St. Luke's Hospital tt the University of Buffalo. ..
  10. HIV/STI Prevention for Drug-Involved Couples
    Nabila El Bassel; Fiscal Year: 2006
    ..Sharp from St. Luke's Hospital in New York City, and Dr. Fals-Stewart from the Research Institute on Addictions at the University of Buffalo. [unreadable] [unreadable] [unreadable]..
  11. HIV Intervention Science Training Program for Minority New Investigators
    Nabila El Bassel; Fiscal Year: 2008
    ..All these Centers have been collaborating on HIV, trauma/PTSD, and/or health disparities research and have designed mechanisms of collaborations that would serve vehicles of training of the REM new investigators. ..
  12. PARTNER ABUSE AND HIV IN WOMEN RECEIVING EMERGENCY CARE
    Nabila El Bassel; Fiscal Year: 2002
    ....
  13. PARTNER ABUSE AND HIV IN WOMEN RECEIVING EMERGENCY CARE
    Nabila El Bassel; Fiscal Year: 2002
    ....
  14. HIV RISK AND PARTNER VIOLENCE--MEN ON METHADONE
    Nabila El Bassel; Fiscal Year: 2002
    ..Data from the proposed study will help inform assessment, treatment and referral protocols to reduce partner violence and HIV-risk behaviors among men and women in MMTPs. ..
  15. HIV/STI Prevention for Drug-Involved Couples
    Nabila El Bassel; Fiscal Year: 2007
    ..Dr. E1-Bassel, the Social Intervention Group Behavioral Studies at the NY State Psychiatric the study: Dr. Steinglass from the Ackerman Angeles, Dr. Sharp from St. Luke's Hospital tt the University of Buffalo. ..
  16. HIV/STD Risk Reduction For African American Couples
    Nabila El Bassel; Fiscal Year: 2006
    ..The findings will contribute significantly to the field of HIV/STI risk reduction by developing and testing an intervention with African American couples that can be offered to HIV clinics and CBOs. ..
  17. HIV/STI Prevention for Drug-Involved Couples
    Louisa Gilbert; Fiscal Year: 2008
    ..Sharp from St. Luke's Hospital in New York City, and Dr. Fals-Stewart from the Research Institute on Addictions at the University of Buffalo. [unreadable] [unreadable] [unreadable]..
  18. HIV/STI Risks Among Migrant Market Workers in Kazakhstan
    Nabila El Bassel; Fiscal Year: 2010
    ..The findings from this study will inform future prevention efforts to stem heterosexual transmission of HIV and STIs in Central Asia among male migrant workers. ..
  19. HIV RISK AND PARTNER VIOLENCE--MEN ON METHADONE
    Nabila El Bassel; Fiscal Year: 1999
    ..Data from the proposed study will help inform assessment, treatment and referral protocols to reduce partner violence and HIV-risk behaviors among men and women in MMTPs. ..
  20. HIV/STI Prevention for Drug-Involved Couples
    Nabila El Bassel; Fiscal Year: 2005
    ..Long shore from the University of California at Los Angeles, Dr. Sharp from St. Luke's Hospital in New York City, and Dr. Fals-Stewart from the Research Institute on Addictions at the University of Buffalo. ..
  21. HIV/STD Risk Reduction For African American Couples
    Nabila El Bassel; Fiscal Year: 2006
    ..The findings will contribute significantly to the field of HIV/STI risk reduction by developing and testing an intervention with African American couples that can be offered to HIV clinics and CBOs. ..
  22. Couples-Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan
    Nabila El Bassel; Fiscal Year: 2008
    ..There is a race to develop and implement effective HIV preventive interventions for IDUs and their sexual partners to stem the spread of HIV, HCV and other STIs in Shu and other Central Asian towns along drug trafficking routes. ..
  23. Preventing HIV and other STDs among drug-involved women
    Nabila El Bassel; Fiscal Year: 2005
    ..The SWRD Program will be directed by Dr. Nabila El-Bassel and co-directed by Drs. Steven Schinke and Mary McKay, all CUSSW faculty with strong programs of federally funded research related to substance abuse and HIV. ..
  24. HIV RISK AND PARTNER VIOLENCE--MEN ON METHADONE
    Nabila El Bassel; Fiscal Year: 2000
    ..Data from the proposed study will help inform assessment, treatment and referral protocols to reduce partner violence and HIV-risk behaviors among men and women in MMTPs. ..
  25. Intervention to Close Digital Divide in AIDS Care
    Seth Kalichman; Fiscal Year: 2003
    ..If successful, the experimental intervention could be readily implemented as a community-based program by AIDS Service Organizations, health centers, and community-based Internet access providers. ..
  26. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2005
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  27. HIV TREATMENT ADHERENCE FOR PERSONS WITH LOW-LITERACY
    Seth Kalichman; Fiscal Year: 2000
    ..Results of the proposed research will provide critical information about improving HIV treatment adherence with low-literacy populations that is needed prior to conducting larger and more expensive clinical trials. ..
  28. Training in Social Processes of HIV/AIDS
    Seth Kalichman; Fiscal Year: 2008
    ..Trainees will work with a community based AIDS service organization to conduct a field study that will serve as a rich training experience for them and will directly benefit the partner organization. ..
  29. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2006
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  30. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2006
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  31. Multilevel Alcohol-HIV/AIDS Prevention in South Africa
    Seth Kalichman; Fiscal Year: 2008
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  32. HIV Treatment Adherence Intervention for People with Poor Literacy Skills
    Seth Kalichman; Fiscal Year: 2008
    ..Effective strategies for improving adherence in patients with poor health literacy must be tailored to achieve optimal adherence and therefore viral suppression. ..
  33. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2009
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  34. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2006
    ..It will be conducted within a large and on-going ARV cohort established as a collaborative project between a South African industrial conglomerate and Johns Hopkins University. [unreadable] [unreadable]..
  35. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2007
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  36. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2006
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  37. Training in Social Processes of HIV/AIDS
    Seth Kalichman; Fiscal Year: 2007
    ..Trainees will work with a community based AIDS service organization to conduct a field study that will serve as a rich training experience for them and will directly benefit the partner organization. ..
  38. Multilevel Alcohol-HIV/AIDS Prevention in South Africa
    Seth Kalichman; Fiscal Year: 2007
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  39. Alcohol-Related HIV Risks among South African Women
    Seth Kalichman; Fiscal Year: 2008
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  40. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2001
    ..Results of the proposed study will guide the allocation of HIV prevention resources in establishing brief and effective HIV risk reduction counseling services for populations vulnerable to HIV infection. ..
  41. Intervention to Close Digital Divide in AIDS Care
    Seth Kalichman; Fiscal Year: 2001
    ..If successful, the experimental intervention could be readily implemented as a community-based program by AIDS Service Organizations, health centers, and community-based Internet access providers. ..
  42. Gender Violence and HIV Risk Reduction in South Africa
    Seth Kalichman; Fiscal Year: 2004
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,600 new HIV infections in South Africa each day...
  43. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2000
    ..Results of the proposed study will guide the allocation of HIV prevention resources in establishing brief and effective HIV risk reduction counseling services for populations vulnerable to HIV infection. ..
  44. Intervention to Close Digital Divide in AIDS Care
    Seth Kalichman; Fiscal Year: 2004
    ..If successful, the experimental intervention could be readily implemented as a community-based program by AIDS Service Organizations, health centers, and community-based Internet access providers. ..
  45. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2009
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  46. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2008
    ..It will be conducted within a large and on-going ARV cohort established as a collaborative project between a South African industrial conglomerate and Johns Hopkins University. [unreadable] [unreadable]..
  47. HIV TREATMENT ADHERENCE FOR PERSONS WITH LOW-LITERACY
    Seth Kalichman; Fiscal Year: 2002
    ..Results of the proposed research will provide critical information about improving HIV treatment adherence with low-literacy populations that is needed prior to conducting larger and more expensive clinical trials. ..
  48. HIV TREATMENT ADHERENCE FOR PERSONS WITH LOW-LITERACY
    Seth Kalichman; Fiscal Year: 2001
    ..Results of the proposed research will provide critical information about improving HIV treatment adherence with low-literacy populations that is needed prior to conducting larger and more expensive clinical trials. ..
  49. Gender Violence and HIV Risk Reduction in South Africa
    Seth Kalichman; Fiscal Year: 2006
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,600 new HIV infections in South Africa each day...
  50. HIV Treatment Adherence Intervention for People with Poor Literacy Skills
    Seth Kalichman; Fiscal Year: 2009
    ..Effective strategies for improving adherence in patients with poor health literacy must be tailored to achieve optimal adherence and therefore viral suppression. ..
  51. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2005
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  52. Multilevel Alcohol-HIV/AIDS Prevention in South Africa
    Seth C Kalichman; Fiscal Year: 2010
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  53. Alcohol-Related HIV Risks among South African Women
    Kathleen J Sikkema; Fiscal Year: 2010
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  54. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2007
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  55. Alcohol and HIV Risk Reduction in South Africa
    Seth Kalichman; Fiscal Year: 2006
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  56. Gender Violence and HIV Risk Reduction in South Africa
    Seth Kalichman; Fiscal Year: 2005
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,600 new HIV infections in South Africa each day...
  57. Gender Violence and HIV Risk Reduction in South Africa
    Leickness Simbayi; Fiscal Year: 2007
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,600 new HIV infections in South Africa each day...
  58. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2008
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  59. Intervention to Close Digital Divide in AIDS Care
    Seth Kalichman; Fiscal Year: 2002
    ..If successful, the experimental intervention could be readily implemented as a community-based program by AIDS Service Organizations, health centers, and community-based Internet access providers. ..
  60. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2008
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  61. HIV TREATMENT ADHERENCE FOR PERSONS WITH LOW-LITERACY
    Seth Kalichman; Fiscal Year: 2001
    ..Results of the proposed research will provide critical information about improving HIV treatment adherence with low-literacy populations that is needed prior to conducting larger and more expensive clinical trials. ..
  62. Alcohol-Related HIV Risks among South African Women
    Seth Kalichman; Fiscal Year: 2009
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  63. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2001
    ..Results of the proposed study will guide the allocation of HIV prevention resources in establishing brief and effective HIV risk reduction counseling services for populations vulnerable to HIV infection. ..
  64. Multilevel Alcohol-HIV/AIDS Prevention in South Africa
    Seth Kalichman; Fiscal Year: 2009
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  65. HIV Treatment Adherence Intervention for People with Poor Literacy Skills
    Seth C Kalichman; Fiscal Year: 2010
    ..Effective strategies for improving adherence in patients with poor health literacy must be tailored to achieve optimal adherence and therefore viral suppression. ..
  66. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2005
    ..abstract_text> ..
  67. TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
    Adeline Nyamathi; Fiscal Year: 2002
    ....
  68. Treatment Intensification for Drug-Resistant HIV
    Steven Deeks; Fiscal Year: 2004
    ..Funding for the pilot clinical trial has been obtained from other sources; funding is requested in this proposal only for costs associated with the measurements of immunologic response to drug-resistant HIV-1. ..
  69. HIV Prevention trials Network (HPTN) Coordinating and Operations Center
    Sten Vermund; Fiscal Year: 2008
    ..Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide). ..
  70. TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
    Adeline Nyamathi; Fiscal Year: 2001
    ....
  71. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  72. Immunologic Control of Drug-resistant HIV-1
    Steven Deeks; Fiscal Year: 2003
    ..Finally, since we will estimate the relative in vivo thresholds for HIV-mediated immunogenicity and pathogenicity, these studies may also have implications for vaccine development. ..
  73. Enhancing HIV Medication Adherence in India
    Deborah Jones; Fiscal Year: 2009
    ....
  74. HIV Prevention trials Network (HPTN) Coordinating and Operations Center
    Sten Vermund; Fiscal Year: 2007
    ..Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide). ..
  75. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
    ....
  76. Community-Based Approach to Designing an AIDS Program for HIV+ Mothers in India
    Adeline Nyamathi; Fiscal Year: 2008
    ..These findings will lead to future funding to actually develop and test a newly designed program. [unreadable] [unreadable] [unreadable]..
  77. TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
    Adeline Nyamathi; Fiscal Year: 1999
    ....
  78. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
    ....
  79. Implementing HIV Risk Reduction Zambia
    Deborah Jones; Fiscal Year: 2008
    ....
  80. Immunologic Control of Drug-resistant HIV-1
    Steven Deeks; Fiscal Year: 2002
    ..Finally, since we will estimate the relative in vivo thresholds for HIV-mediated immunogenicity and pathogenicity, these studies may also have implications for vaccine development. ..
  81. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  82. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
    Bruce R Schackman; Fiscal Year: 2010
    ....
  83. Topical Immune modulatory strategies to prevent HIV transmission
    Michael Lederman; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  84. POL and Access Intervention to Reduce HIV Stigma among Service Providers in China
    Li Li; Fiscal Year: 2007
    ..The number of annual reported HIV infections in China has increased steadily...
  85. Comprehensive HIV Testing Strategies for Jails
    Curt Beckwith; Fiscal Year: 2007
    ..Beckwith will be mentored by Dr. Timothy P. Flanigan from Brown Medical School in Providence, Rl. Through this award, Dr. Beckwith aims to advance the delivery of HIV testing and prevention services to persons incarcerated in jail. ..
  86. Genotypic and Phenotypic Characterization of Heterosexually Transmitted HIV-1
    Manish Sagar; Fiscal Year: 2009
    ..We will explore the biological relevance of observed differences in these phenotypic properties to develop potential biological models for selection during HIV-1 transmission. ..
  87. HIV PREVENTION TRIAL UNIT
    David Metzger; Fiscal Year: 2006
    ..Thus, an additional aim of our group is to be active participants in three of the PTN science working groups-Microbicides, Behavioral Intervention, and Substance Related Transmission. ..
  88. Influences on the translation of an evidence-based HIV/STI intervention into prac
    M Margaret Dolcini; Fiscal Year: 2009
    ..abstract_text> ..
  89. Nucleophilic Antibodies: Characterization and Induction
    Sudhir Paul; Fiscal Year: 2009
    ..From these studies, we hope to identify the strengths and weaknesses of the Abs and immunogens relevant to HIV vaccination and therapy. ..
  90. beta-Amyloid Antibodies with Specific Proteolytic Activity
    Sudhir Paul; Fiscal Year: 2008
    ..Proteolytic anti-Abeta Abs capable of preventing the deposition of Abeta and cognitive decline would be candidates for passive immunotherapy of humans with AD. ..
  91. Genotypic and Phenotypic Characterization of Heterosexually Transmitted HIV-1
    Manish Sagar; Fiscal Year: 2010
    ..We will explore the biological relevance of observed differences in these phenotypic properties to develop potential biological models for selection during HIV-1 transmission. ..
  92. 2007 Case CFAR Annual Spring Conference
    Michael Lederman; Fiscal Year: 2007
    ..The Case CFAR is proactive in its efforts to ensure inclusion of minority and female researchers in[unreadable] all aspects of Conference planning and attendance. ..
  93. Help Us, Save Us! HIV/STI Prevention Intervention for High-Risk Black Men
    JOHN JEMMOTT; Fiscal Year: 2008
    ..This study will provide an urgently needed intervention to reduce the risk of HIV and other STIs in one of the highest risk populations in the United States. ..
  94. Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission
    Michael Lederman; Fiscal Year: 2008
    ..This approach will generate better and safer CCR5 inhibitors that can be produced on a scale suitable for stopping the spread of HIV/AIDS in the most-impacted areas. ..